Import from '@/components/mdx'

CJC-1295 for ACL and Ligament Rehabilitation: A Women's Protocol Guide

What CJC-1295 Is and How It Works in Women

CJC-1295 stimulates your pituitary to release growth hormone (GH) in a pulsatile, physiological pattern rather than flooding receptors with exogenous GH. That distinction matters because pulsatile GH release is how your body normally drives IGF-1 production in the liver, and IGF-1 is the downstream signal most responsible for collagen cross-linking and ligament matrix repair.

The version most commonly used clinically is CJC-1295 with DAC (Drug Affinity Complex), which extends the half-life from roughly 30 minutes to 6-8 days by covalently binding to albumin. A shorter-acting variant, CJC-1295 without DAC (also called Mod GRF 1-29), has a half-life of approximately 30 minutes and is preferred by practitioners who want tighter control over GH pulse timing, particularly in women who are more sensitive to GH fluctuations across their cycle.

Why Women's GH Physiology Is Different

Your baseline GH secretion is not the same as a man's. Women produce two to three times more GH pulses per 24 hours than age-matched men, and estrogen amplifies pituitary GH release. This means:

• Premenopausal women often need the lower end of published dose ranges to avoid excessive IGF-1 elevation.
• Perimenopausal and postmenopausal women lose this estrogen-driven amplification and may need modest upward titration, but still start low.
• GH sensitivity also shifts across the menstrual cycle. IGF-1 tends to be slightly lower in the follicular phase and higher around ovulation. Timing your monitoring labs to the same cycle phase each month gives more consistent data.

How Connective Tissue Repair Is Linked to GH and IGF-1

Ligaments and tendons are collagen-dense structures with poor vascular supply and notoriously slow intrinsic healing. IGF-1 receptors are expressed on tenocytes and ligamentocytes. In rodent models, IGF-1 infusion increased collagen synthesis and tensile strength in healing ligaments by roughly 30-40% compared to saline controls. The anterior cruciate ligament (ACL) is especially studied because it heals poorly without surgical reconstruction.

The hypothesis driving CJC-1295 use in orthopedic rehab is that raising endogenous IGF-1 through physiological GH pulsatility replicates some of the benefits seen with direct IGF-1 infusion, without the hypoglycemic and mitogenic risks of injecting IGF-1 directly.

The Evidence Base: What Is Proven and What Is Not

Honesty is required here. The evidence hierarchy for CJC-1295 specifically in ACL and ligament rehabilitation is thin, and you deserve a clear-eyed account of what has been studied in whom.

Animal Data (Strongest Available for Ligament Healing)

Rodent and rabbit studies show that GHRH analogue treatment after tendon or ligament injury increases collagen type I deposition, accelerates fibroblast proliferation, and improves load-to-failure metrics. These findings are promising. They are also not directly transferable to a 35-year-old woman recovering from ACL reconstruction.

Human GH and Tendon Data (Observational and Extrapolated)

A 2010 randomized controlled trial in GH-deficient adults found that GH replacement increased tendon collagen synthesis rate by approximately 26% over 4 weeks. Participants were adults with confirmed GH deficiency, not healthy athletes. The majority were men. Women in that cohort required dose adjustment because IGF-1 rose disproportionately at the same weight-based dose.

The GHRH-analogue literature more broadly documents that CJC-1295 with DAC at doses of 1-2 mg once or twice weekly produces sustained IGF-1 elevation of 2-3 times baseline in healthy adults. No ACL-specific human RCT has been completed using CJC-1295. This is an important gap.

Practitioner-Observational and Anecdotal Experience

Sports medicine and peptide-prescribing clinicians report that patients using CJC-1295 alongside structured physical therapy show subjectively faster return-to-sport timelines and lower pain scores at 12 and 16 weeks post-reconstruction. These reports are not controlled, not blinded, and carry significant confounding from concurrent interventions including diet, physical therapy intensity, sleep optimization, and other peptides such as BPC-157 or TB-500.

Evidence Level Summary:

| Claim | Evidence Level | |---|---| | CJC-1295 raises IGF-1 in humans | Level 1 (RCT) | | GH increases tendon collagen synthesis | Level 2 (RCT, mostly men) | | GHRH analogues aid ligament healing | Level 3 (animal RCTs) | | CJC-1295 accelerates ACL rehab in women | Level 5 (anecdotal) |

Women have been under-represented in every tier of this research. The tendon collagen synthesis RCT cited above enrolled mostly male participants. The rodent studies use male animals in approximately 70% of cases, a pattern well-documented across pre-clinical musculoskeletal research. Any protocol derived from this literature requires conservative extrapolation when applied to women.

A Structured Protocol for Women Using CJC-1295 in ACL Rehabilitation

This protocol reflects current practitioner consensus and the available human GH physiology data. It is not a prescription. Any peptide use should be supervised by a licensed clinician familiar with GH-axis pharmacology.

Phase 1: Weeks 1-4 (Initiation and Titration)

Starting dose: 100 mcg of CJC-1295 without DAC (Mod GRF 1-29), subcutaneous injection, 3 times per week on non-consecutive days.

Injecting at bedtime aligns with your natural nocturnal GH surge and may produce a larger peak IGF-1 response than morning dosing. Use the periumbilical subcutaneous fat or the lateral thigh; rotate sites to avoid lipodystrophy.

During this phase, the goal is confirming tolerability. Common early side effects include transient facial flushing, water retention in the hands and ankles, and mild tingling at the injection site. These typically resolve within the first two weeks.

Monitoring at week 4: Fasting IGF-1, fasting glucose, and HbA1c. Target IGF-1 in the upper quartile of your age-matched normal range, not above it. In premenopausal women aged 25-40, the upper limit of the age-adjusted normal range for IGF-1 is approximately 250-350 ng/mL depending on the assay. Aim for 200-280 ng/mL and do not chase numbers at the top of the range.

Phase 2: Weeks 5-12 (Active Healing Phase)

Dose adjustment: If week 4 IGF-1 is below 180 ng/mL and glucose is stable, you may increase to 150 mcg three to five times weekly. If IGF-1 is already at 250 ng/mL or above, hold the starting dose.

This phase overlaps with the biological window of maximal ligament remodeling. In ACL graft biology, the graft undergoes ligamentization over a 12-24 month period, with the most active collagen remodeling occurring in weeks 6-16 post-surgery. CJC-1295 is hypothesized to support this window by sustaining an anabolic IGF-1 environment.

Pair injections with your physical therapy schedule, ideally dosing 60-90 minutes before a PT session to allow GH peak to align with mechanical loading. Mechanical loading and GH signaling appear to be synergistic in stimulating tenocyte collagen production in vitro.

Nutrition during phase 2: Protein intake of at least 1.6 g per kg of body weight per day is needed to supply the amino acid substrate for collagen synthesis. Vitamin C at 500 mg taken 30-60 minutes before collagen-rich protein or gelatin further supports collagen cross-linking. These are not optional adjuncts; the peptide cannot synthesize collagen from nothing.

Phase 3: Weeks 13-16 (Consolidation or Taper)

By week 12, reassess with a second IGF-1, fasting glucose, and HbA1c panel. If you are tracking toward return-to-sport testing and values are within target range, you may continue at the established dose through week 16. If IGF-1 has exceeded the upper normal range at any point, reduce dose by 25 mcg increments and recheck in four weeks.

After week 16, take a minimum four-week break from CJC-1295 before any repeat cycle. Extended continuous use risks pituitary desensitization to GHRH signaling, though the precise duration at which this becomes clinically significant in women is not well-characterized in the literature.

Life-Stage-Specific Dosing Adjustments

Reproductive years (ages 18-40): Start at 100 mcg. Estrogen-driven GH amplification makes this population most likely to achieve target IGF-1 at lower doses.

Trying to conceive: Stop CJC-1295 at least one full menstrual cycle before attempting conception. See the pregnancy section below.

Perimenopause (typically ages 40-52): Estrogen fluctuations mean GH pulsatility is less predictable. Start at 100 mcg; titrate based on IGF-1 labs rather than dose assumptions. Water retention side effects are more pronounced in perimenopausal women and may overlap with estrogen-withdrawal fluid shifts, complicating symptom tracking.

Post-menopause: Endogenous GH is lower. A starting dose of 100 mcg is still appropriate, but some postmenopausal women who are not on hormone therapy may need to reach 150-200 mcg to achieve target IGF-1. If you are on estrogen-containing hormone therapy, oral estrogen raises IGF-1 binding protein levels and may blunt the peripheral IGF-1 response, whereas transdermal estrogen has a smaller effect on hepatic IGF-1 metabolism. This is a real pharmacokinetic difference that your prescribing clinician should factor in.

Pregnancy, Lactation, and Contraception

CJC-1295 is contraindicated in pregnancy. This is a firm stop.

No human safety data exists for CJC-1295 in pregnancy. GH-axis peptides cross into the fetal circulation in animal models. Growth hormone excess in early pregnancy is associated with fetal macrosomia and gestational metabolic disruption in animal studies. The FDA has not assigned a formal pregnancy category to CJC-1295 because it is not an approved pharmaceutical. The clinical consensus is to treat it as contraindicated.

Contraception requirement: If you are sexually active and not trying to conceive, use reliable contraception throughout any CJC-1295 cycle. An ACL injury often occurs in high-activity life phases, ages 15-35, where accidental pregnancy is possible. Do not assume that athletic training suppresses ovulation reliably enough to substitute for contraception.

Discontinuation before conception: Stop CJC-1295 at least 4 weeks before a planned conception attempt given the DAC-formulation's extended half-life (6-8 days means five half-lives equals roughly 30-40 days to near-complete clearance). For the shorter Mod GRF 1-29 variant, clearance is faster, but a 2-week washout minimum is still recommended.

Lactation: No human data on transfer into breast milk exists for CJC-1295. GH and IGF-1 are naturally present in breast milk and play a role in infant gut development, but exogenous GHRH analogues have not been studied in lactating women. The precautionary position is to avoid CJC-1295 during breastfeeding.

Postpartum: Women who sustained ACL injuries during pregnancy or who are now post-partum and cleared for exercise may wish to discuss peptide options with their provider. Postpartum is a period of significant hormonal flux, and IGF-1 levels are naturally altered by lactation status. The protocol above does not apply without modification in the postpartum period, and individualized lab-guided dosing is especially important.

Who This Protocol Is Right For and Who Should Avoid It

Likely Appropriate

• Women aged 18-55 with confirmed ACL reconstruction or grade II/III ligament injury, at least 2 weeks post-surgical clearance
• Women with documented low-normal IGF-1 for age at baseline
• Women who are committed to structured physical therapy alongside peptide use
• Women who can access regular lab monitoring (IGF-1, glucose, HbA1c at minimum)

Proceed with Caution

• Women with PCOS: IGF-1 signaling is already dysregulated in many women with PCOS, and excessive IGF-1 elevation may worsen hyperandrogenism or insulin resistance. Lower starting doses and more frequent monitoring apply.
• Women with a personal or family history of any GH-sensitive cancer, including breast cancer. IGF-1 is a mitogen. The relationship between IGF-1 levels and breast cancer risk is documented in prospective cohort data, though whether short-term supraphysiologic IGF-1 from CJC-1295 cycles carries meaningful risk is unknown.
• Women with pre-diabetes or insulin resistance: CJC-1295 can transiently raise fasting glucose, particularly in the first 4-6 weeks. Baseline HbA1c should be below 5.7% before starting.
• Women with active thyroid disease: GH stimulates thyroid hormone metabolism and may precipitate relative hypothyroidism. Include a thyroid panel in baseline and 8-week labs.

Not Appropriate

• Pregnant women (see above)
• Breastfeeding women (see above)
• Women with active malignancy of any type
• Women with acromegaly or confirmed GH excess at baseline
• Women with uncontrolled diabetes (HbA1c above 8%)

Monitoring Labs: What to Check and When

Structured monitoring is not optional. CJC-1295 is not a supplement. It is a pharmacologically active peptide that alters GH-axis signaling, and the consequences of IGF-1 overdriving are real.

| Timepoint | Labs | |---|---| | Baseline (before first dose) | Fasting IGF-1, fasting glucose, HbA1c, TSH, free T4, CBC, CMP | | Week 4 | Fasting IGF-1, fasting glucose | | Week 8 | Fasting IGF-1, fasting glucose, HbA1c, TSH | | Week 12-16 (end of cycle) | Full panel as baseline | | 4 weeks post-cycle | Fasting IGF-1 (to confirm return to baseline) |

If IGF-1 at any point exceeds the age-adjusted upper limit of normal, reduce dose by 25 mcg and recheck in 3 weeks before continuing.

Combining CJC-1295 With Other Interventions in Rehab

CJC-1295 is almost never used in isolation in practitioner-supervised orthopedic rehab settings. It is most commonly paired with:

BPC-157: A body protection compound peptide with direct evidence of accelerated tendon-to-bone healing in rat models at 10 mcg/kg. No human RCTs exist. The two peptides are hypothesized to act on different pathways (BPC-157 on vascular growth and local repair; CJC-1295 on systemic IGF-1).

Collagen peptide supplementation: 15 g of hydrolyzed collagen with 50 mg vitamin C before exercise increased collagen synthesis markers in a small RCT of 8 men. This study enrolled men only. The finding is directionally plausible for women but directly extrapolated, not proven.

Progesterone-phase considerations: Animal and limited human data suggest that progesterone may have a protective effect on ligament laxity during the luteal phase. Your highest-risk period for re-injury of a healing ligament may be the late follicular and periovulatory phase when estrogen is high and progesterone is low. This does not change the CJC-1295 protocol directly, but it informs the physical therapy loading schedule your PT should know about.

Expected Timeline of Outcomes

Return-to-sport after ACL reconstruction without any peptide protocol is typically 9-12 months when clearance is based on objective functional testing. This is the baseline you are trying to improve.

Based on practitioner observational experience and the extrapolated tissue-biology data, realistic expectations for women using CJC-1295 alongside structured rehab are:

• Reduced post-surgical swelling and pain at weeks 4-8 (most consistently reported)
• Earlier achievement of quad strength symmetry index milestones at weeks 10-14
• Possible reduction in overall timeline to return-to-sport criteria by 4-8 weeks

These are estimates, not guarantees. No controlled human trial has measured time-to-return-to-sport as a primary endpoint with CJC-1295. State this clearly to any patient or reader.